Calidi Biotherapeutics RedTail Platform Data

Atara Biotherapeutics, a biotechnology company, is advancing its RedTail platform for targeted genetic medicines. The company presented new data at the American Association for Cancer Research annual meeting in San Diego on April 19, 2026, demonstrating its approach to activating T-cells and inducing T-cell engagers in the tumor microenvironment. Atara Biotherapeutics will also present data at the American Society of Gene and Cell Therapy annual meeting in Boston on May 14, 2026. Its lead candidate, CLD-401, engineered to express IL-15 SA, is in IND-enabling studies, with an Investigational New Drug (IND) application expected to be filed with the United States — Food and Drug Administration by the end of 2026. The RedTail platform aims to overcome limitations in solid tumor therapies by confining T-cell engager expression to the tumor microenvironment, limiting off-tumor toxicity. Eric Poma and Antonio F. Santidrian, key figures at Atara Biotherapeutics, highlighted the platform's potential.